LCentre for Primary Care, Division of Population Health, Health Services Research & Primary Care, Williamson Building, Oxford Road, Manchester, M13 9PL, UK.
Centre for Reviews and Dissemination, A/B Block, Alcuin College, University of York, York, YO10 5DD, UK.
Syst Rev. 2018 Aug 8;7(1):117. doi: 10.1186/s13643-018-0766-x.
Clinical study reports (CSRs) are produced for marketing authorisation applications. They often contain considerably more information about, and data from, clinical trials than corresponding journal publications. Use of data from CSRs might help circumvent reporting bias, but many researchers appear to be unaware of their existence or potential value. Our survey aimed to gain insight into the level of familiarity, understanding and use of CSRs, and to raise awareness of their potential within the systematic review community. We also aimed to explore the potential barriers faced when obtaining and using CSRs in systematic reviews.
Online survey of systematic reviewers who (i) had requested or used CSRs, (ii) had considered but not used CSRs and (iii) had not considered using CSRs was conducted. Cochrane reviewers were contacted twice via the Cochrane monthly digest. Non-Cochrane reviewers were reached via journal and other website postings.
One hundred sixty respondents answered an open invitation and completed the questionnaire; 20/160 (13%) had previously requested or used CSRs and other regulatory documents, 7/160 (4%) had considered but not used CSRs and 133/160 (83%) had never considered this data source. Survey respondents mainly sought data from the European Medicines Agency (EMA) and/or the Food and Drug Administration (FDA). Motivation for using CSRs stemmed mainly from concerns about reporting bias 11/20 (55%), specifically outcome reporting bias 11/20 (55%) and publication bias 5/20 (25%). The barriers to using CSRs noted by all types of respondents included current limited access to these documents (43 respondents), the time and resources needed to obtain and include these data in evidence syntheses (n = 25) and lack of guidance about how to use these sources in systematic reviews (n = 26).
Most respondents (irrespective of whether they had previously used them) agreed that access to CSRs is important, and suggest that further guidance on how to use and include these data would help to promote their use in future systematic reviews. Most respondents who received CSRs considered them to be valuable in their systematic review and/or meta-analysis.
临床研究报告(CSRs)是为药物上市许可申请而编写的。它们通常包含比相应的期刊出版物更多的关于临床试验的信息和数据。使用 CSRs 中的数据可能有助于避免报告偏倚,但许多研究人员似乎没有意识到它们的存在或潜在价值。我们的调查旨在深入了解系统评价界对 CSRs 的熟悉程度、理解程度和使用情况,并提高对它们潜在价值的认识。我们还旨在探讨在系统评价中获取和使用 CSRs 时面临的潜在障碍。
对曾经请求或使用过 CSRs、曾经考虑但未使用过 CSRs 以及从未考虑过使用 CSRs 的系统评价人员进行了在线调查。通过 Cochrane 每月文摘向 Cochrane 审查员进行了两次联系。通过期刊和其他网站发布信息联系了非 Cochrane 审查员。
160 名应答者对公开邀请做出了回应并完成了调查问卷;20/160(13%)曾请求或使用过 CSRs 和其他监管文件,7/160(4%)曾考虑但未使用过 CSRs,133/160(83%)从未考虑过这一数据来源。调查应答者主要从欧洲药品管理局(EMA)和/或美国食品和药物管理局(FDA)获取数据。使用 CSRs 的动机主要源于对报告偏倚的担忧 11/20(55%),特别是结局报告偏倚 11/20(55%)和发表偏倚 5/20(25%)。所有类型的应答者都提到使用 CSRs 的障碍包括目前对这些文件的访问有限(43 名应答者)、获取和纳入这些数据到证据综合中的时间和资源需求(25 名应答者)以及缺乏关于如何在系统评价中使用这些来源的指导(26 名应答者)。
大多数应答者(无论他们之前是否使用过)都认为获取 CSRs 很重要,并建议提供更多关于如何使用和纳入这些数据的指导,以帮助促进它们在未来系统评价中的使用。大多数收到 CSRs 的应答者认为它们在他们的系统评价和/或荟萃分析中很有价值。